Tat-Gap 19 TFA

CAT: 0013-GTR19035827-01Size: 500 µgDry Ice: NoHazardous: No

1 / 1

CAT#:0013-GTR19035827-01Size:500 µg

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Description

Tat-Gap 19 is a Cx43 hemichannel inhibitor derived from the HIV-1 Tat domain. It blocks ATP release in vitro (10 μM) and shows in vivo efficacy by reducing cerebral infarct volume (25 mg/kg) and liver fibrosis (1 mg/kg/day) in rodent injury models.

Field of Research

Immunology & Inflammation

Molecular Weight

2703.25

Storage Conditions

-20°C

Notes

For research use only.

Related Products

Catalog	Name
GTR19037190-01	TAT-Gap19 TFA
GTR19036531-01	TAT-14 TFA
GTR19035786-01	Tat-CBD3 TFA
GTR19144215-01	TAT-amide TFA
GTR19035810-01	TRPV1-Tat TFA
GTR19035748-01	Tat-QFNP12 TFA
GTR19030399	Tat-NR2B9c TFA
GTR19036567-01	TAT peptide TFA
GTR19036406-01	Tat-NR2Baa TFA
GTR19035788-01	Tat-CIRP TFA

Alternative Products

Catalog	Name
T83682-01	Tat-Gap 19 TFA
068-27	TAT Derivative, R9-Tat
abx600294-01	Protein Tat (TAT) Protein
HY-P0281-01	TAT
E8ER1919-19	α-TAT
CRB1001142-01	TAT - GluR23Y - (TAT Conjugated Peptides)
C13526-5mg	Tat-beclin 1 (Tat-BECN1)
CRB1001584-01	TAT-CN21 - (TAT Conjugated Peptides)

Tat-Gap 19 TFA

Related Products

Alternative Products

Popular Products